NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

Honasa Consumer Approves First Ever Dividend

The Board of Directors at Honasa Consumer, the parent company of Mamaearth, Aqualogica, and The Derma Co, has given its approval for a final dividend of ₹3 per equity share. This is the company's first ever dividend payout, and it comes after a record quarterly net profit of ₹69.4 crore in the March quarter, which represents a nearly 178% increase from the year-ago period on a consolidated basis.

The proposed dividend payout of ₹98 crore, subject to shareholder approval at the annual general meeting, accounts for approximately 51% of Honasa's FY26 standalone net profit, as per filings with the stock exchanges. The company's revenue from operations surged 23% year-on-year to ₹657 crore in the March quarter.

In FY26, Honasa's net profit soared to ₹200 crore from ₹72.6 crore the previous year, while operating revenue grew by a modest 15% year-on-year to ₹2,391 crore, driven by the strong performance of its younger brands such as The Derma Co and Aqualogica.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

QuarterNet Profit (₹ crore)Revenue Growth (year-on-year)
Q4 FY2669.423%
FY2620015%

Honasa's revenue growth was led by its younger brands, including Dr Sheth's, Staze, and Bblunt, which grew 40% sequentially. The Derma Co and its newest addition Reginald Men led the pack, with The Derma Co currently having a "double-digit Ebitda profile" and Reginald Men hitting an annualized run rate (ARR) of over ₹100 crore while doubling revenue year-on-year.

Mamaearth, Honasa's flagship brand, grew in the mid-teens during the quarter and saw its market share in key categories, such as face cleansers and shampoos, increase by as much as 120 basis points over the past year. The company's direct distribution model, which resulted in higher expenses and dented bottom lines for more than six quarters, is now finally starting to bear fruit, with nearly 120,000 outlets billed directly through distributors during FY26.

Honasa's Key Financial Highlights

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

  • Net profit: ₹69.4 crore (Q4 FY26)
  • Revenue from operations: ₹657 crore (Q4 FY26)
  • Operating revenue: ₹2,391 crore (FY26)
  • Revenue growth: 15% (year-on-year)
  • Net profit growth: 178% (year-on-year)

The company has also announced that it does not anticipate further price hikes any time soon, as it had implemented price hikes across categories to offset input cost hikes caused by the US-Iran war. Additionally, Honasa's investments in technology, particularly in AI-led content systems and distribution infrastructure, are "beginning to reflect in stronger execution quality".

The Board of Directors has also approved the re-appointment of Subramaniam Somasundaram, the former chief financial officer of Titan Company Ltd, as an independent director for five years.

Honasa's shares closed nearly 1.4% higher on Thursday to settle at ₹361.70 in the NSE.

Investor Takeaway

Investors may consider Honasa Consumer for its strong quarterly performance and potential dividend payout.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.